

This application is a § 371 of WO 98/42377.

Please amend the claims as follows:

Please cancel claims 1-13.

Kindly add the following claims:

14. A method for treating sensitized T cell-mediated diseases, comprising administering to a patient in need thereof a pharmaceutical composition comprising an antibody directed against interleukin-6 (IL-6) receptor and a pharmaceutically acceptable carrier, wherein the sensitized T cell-mediated diseases are multiple sclerosis, uveitis, chronic thyroiditis, delayed hypersensitivity, contact dermatitis, or atopic dermatitis.

15. The method according to claim 14, wherein the antibody directed against IL-6 receptor is a monoclonal antibody.

16. The method according to claim 15, wherein the monoclonal antibody is directed against human IL-6 receptor.

17. The method according to claim 15, wherein the monoclonal antibody is directed against mouse IL-6 receptor.

18. The method according to claim 16, wherein the monoclonal antibody is PM-1 antibody.

19. The method according to claim 17, wherein the monoclonal antibody is MR16-1 antibody.

20. The method according to claim 16, wherein the monoclonal antibody has the constant region of human antibody.